Bank of America
TARS icon

Bank of America’s Tarsus Pharmaceuticals TARS Stock Holding History

Bank of America’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.1M Sell
1,193,182
-1,195
-0.1% -$76.3K ﹤0.01% 1396
2026
Q1 		$83.8M Buy
1,194,377
+436,271
+58% +$30.5M 0.01% 1251
2025
Q4 		$62.1M Buy
758,106
+222,083
+41% +$16.6M ﹤0.01% 1404
2025
Q3 		$31.9M Buy
536,023
+69,743
+15% +$3.43M ﹤0.01% 2156
2025
Q2 		$18.9M Buy
466,280
+37,136
+9% +$1.67M ﹤0.01% 2610
2025
Q1 		$22M Buy
429,144
+91,288
+27% +$4.51M ﹤0.01% 2335
2024
Q4 		$18.7M Buy
337,856
+104,388
+45% +$4.74M ﹤0.01% 2372
2024
Q3 		$7.68M Sell
233,468
-9,644
-4% -$271K ﹤0.01% 3327
2024
Q2 		$6.61M Buy
243,112
+13,620
+6% +$458K ﹤0.01% 3361
2024
Q1 		$8.34M Sell
229,492
-9,331
-4% -$274K ﹤0.01% 3157
2023
Q4 		$4.84M Buy
238,823
+95,531
+67% +$1.6M ﹤0.01% 3579
2023
Q3 		$2.55M Buy
143,292
+18,786
+15% +$332K ﹤0.01% 4037
2023
Q2 		$2.25M Buy
124,506
+101,547
+442% +$1.61M ﹤0.01% 4117
2023
Q1 		$289K Buy
22,959
+7,415
+48% +$108K ﹤0.01% 5728
2022
Q4 		$228K Buy
15,544
+3,924
+34% +$64.9K ﹤0.01% 5841
2022
Q3 		$199K Sell
11,620
-13,326
-53% -$212K ﹤0.01% 5981
2022
Q2 		$364K Buy
24,946
+18,447
+284% +$277K ﹤0.01% 5653
2022
Q1 		$109K Sell
6,499
-4,163
-39% -$77.3K ﹤0.01% 6821
2021
Q4 		$240K Buy
10,662
+4,891
+85% +$127K ﹤0.01% 6397
2021
Q3 		$125K Buy
5,771
+3,811
+194% +$94.3K ﹤0.01% 6595
2021
Q2 		$57K Sell
1,960
-7,277
-79% -$227K ﹤0.01% 6774
2021
Q1 		$298K Buy
9,237
+7,754
+523% +$287K ﹤0.01% 5747
2020
Q4 		$61K Buy
+1,483
New +$42.2K ﹤0.01% 6242

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of America's TARS Position: Q2 2026 in Review

Bank of America reduced its Tarsus Pharmaceuticals (TARS) stake by 0.1% in Q2 2026, selling an estimated $76.3K and leaving 1,193,182 shares worth $75.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1396.

Bank of America first reported a position in TARS in Q4 2020 and has held it in 23 quarters since. The position peaked at $83.8M in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Bank of America held 1,193,182 shares of Tarsus Pharmaceuticals worth $75.1M as of Q2 2026.
  • Bank of America sold 1,195 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $76.3K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #1396 holding.
  • Bank of America first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Bank of America's Tarsus Pharmaceuticals position peaked at $83.8M in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.